论文部分内容阅读
目的 :观察大剂量氯沙坦降低肾小球性蛋白尿的作用 ,探讨氯沙坦治疗蛋白尿的临床合理剂量及可能的作用机制。方法 :本临床观察采用开放实验自身对照的方法 ,对三组肾病性蛋白尿的患者分别服用常规剂量 (5 0mg/d) ,两倍剂量 (10 0mg/d) ,三倍剂量氯沙坦 (15 0mg/d) 8周的患者进行血Cr、BUN、UA及 2 4h尿蛋白定量检测。结果 :氯沙坦能有效降低肾小球性蛋白尿 ,三组治疗前后 2 4h尿蛋白定量均数比较及组间方差分析差异具有显著性。结论 :氯沙坦对肾小球疾病引起蛋白尿有治疗作用 ,在一定剂量范围内 ,随着氯沙坦剂量的增加降低蛋白尿的作用也增强
OBJECTIVE: To observe the effect of high dose losartan on glomerular proteinuria and to explore the clinical reasonable dose and possible mechanism of losartan in the treatment of proteinuria. Methods: The clinical observation using an open experimental self-control method, three groups of patients with nephrotic proteinuria were taken conventional dose (50mg / d), double dose (10mg / d), triple dose of losartan 15 0mg / d) for 8 weeks in patients with blood Cr, BUN, UA and 24 h urinary protein quantitative detection. Results: losartan can effectively reduce glomerular proteinuria, urinary protein in 24 hours before and after treatment, quantitative mean comparison and analysis of variance between groups was significant. CONCLUSION: Losartan has a therapeutic effect on proteinuria caused by glomerular disease. In a certain dose range, the effect of reducing proteinuria increased with the increase of losartan dose